Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart and Radiochemotherapy for Neoadjuvant ESCC
NCT06637163Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of benmelstobart in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Started Oct 2024; status: recruiting.
02
Drugs
benmelstobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06637163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637163.